| scholarly article | Q13442814 |
| P50 | author | Evan Dellon | Q87734596 |
| Glenn T Furuta | Q64517165 | ||
| P2093 | author name string | Alain Schoepfer | |
| Stuart J Spechler | |||
| Ting Wen | |||
| Marc E Rothenberg | |||
| Javier Molina-Infante | |||
| Alfredo J Lucendo | |||
| Alex Straumann | |||
| Edaire Cheng | |||
| David A Katzka | |||
| Ikuo Hirano | |||
| Albert J Bredenoord | |||
| Fouad J Moawad | |||
| Sandeep K Gupta | |||
| PPI-REE Task Force of the European Society of Eosinophilic Oesophagitis (EUREOS) | |||
| P2860 | cites work | Update on basic and clinical aspects of eosinophilic oesophagitis | Q87611491 |
| Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies | Q26860824 | ||
| Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment | Q28252340 | ||
| Common variants at 5q22 associate with pediatric eosinophilic esophagitis | Q28943383 | ||
| Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia | Q33838272 | ||
| Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis | Q33934643 | ||
| Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease | Q34003041 | ||
| Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis. | Q34488489 | ||
| Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells | Q34490922 | ||
| GWAS identifies four novel eosinophilic esophagitis loci | Q34545768 | ||
| Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications | Q34561866 | ||
| Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study | Q34614300 | ||
| Advances in clinical management of eosinophilic esophagitis | Q34619973 | ||
| Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation | Q34892555 | ||
| Molecular, genetic, and cellular bases for treating eosinophilic esophagitis | Q35537424 | ||
| Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study | Q36072597 | ||
| Eosinophils in the esophagus--peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia | Q36545147 | ||
| Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. | Q36553408 | ||
| Effect of proton pump inhibitor on esophageal eosinophilia. | Q36554740 | ||
| Topical Steroid Therapy for the Treatment of Eosinophilic Esophagitis (EoE): A Systematic Review and Meta-Analysis. | Q36751852 | ||
| Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis | Q36832496 | ||
| Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis | Q37098443 | ||
| Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis | Q37562835 | ||
| Eosinophilic esophagitis: updated consensus recommendations for children and adults | Q37863307 | ||
| Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation | Q37959240 | ||
| Pediatric and adult eosinophilic esophagitis: similarities and differences | Q37982116 | ||
| ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). | Q38097271 | ||
| Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. | Q38188754 | ||
| Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. | Q38959847 | ||
| Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases | Q39195375 | ||
| A Japanese case series of 12 patients with esophageal eosinophilia. | Q39281816 | ||
| Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment | Q39370008 | ||
| Eosinophilic esophagitis: interactions with gastroesophageal reflux disease | Q39576931 | ||
| High Prevalence of Response to Proton-pump Inhibitor Treatment in Children With Esophageal Eosinophilia. | Q40379873 | ||
| Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. | Q41163839 | ||
| The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor | Q42622855 | ||
| Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis | Q43969942 | ||
| Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. | Q45966172 | ||
| Acid hypersensitivity in patients with eosinophilic oesophagitis | Q46224681 | ||
| Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia | Q46374558 | ||
| Mucosal concentrations of proinflammatory cytokines and chemokines at gastric cardia: implication of Helicobacter pylori infection and gastroesophageal reflux | Q47387969 | ||
| Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system | Q48636350 | ||
| Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. | Q53328595 | ||
| Histological Response to Fluticasone Propionate in Patients With Eosinophilic Esophagitis Is Associated With Improved Functional Esophageal Mucosal Integrity. | Q53368598 | ||
| Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. | Q53493586 | ||
| Proton Pump Inhibitors Partially Restore Mucosal Integrity in Patients With Proton Pump Inhibitor–Responsive Esophageal Eosinophilia but Not Eosinophilic Esophagitis | Q62527959 | ||
| Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression | Q62616187 | ||
| Association of eosinophilic inflammation with esophageal food impaction in adults | Q81810836 | ||
| Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia | Q81950092 | ||
| Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic oesophagitis | Q82653962 | ||
| Conservative long-term treatment of children with eosinophilic esophagitis | Q84026540 | ||
| Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults | Q85155444 | ||
| Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis | Q86028293 | ||
| Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis | Q86158867 | ||
| Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia | Q86765402 | ||
| PPI-responsive esophageal eosinophilia cannot be distinguished from eosinophilic esophagitis by endoscopic signs | Q87019339 | ||
| Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings | Q87160809 | ||
| Eosinophilic esophagitis and proton pump-responsive esophageal eosinophilia: what is in a name? | Q87489657 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 524-531 | |
| P577 | publication date | 2015-12-18 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis | |
| P478 | volume | 65 |
| Q38805650 | 2015 David Y. Graham Lecture: The First Two Decades Of Eosinophilic Esophagitis-From Acid Reflux To Food Allergy |
| Q64950143 | A 12-Week Maintenance Therapy with a New Prepared Viscous Budesonide in Pediatric Eosinophilic Esophagitis. |
| Q55403880 | A Review of Tertiary Referrals for Management of Pediatric Esophageal Eosinophilia. |
| Q88780272 | A case of Jackhammer esophagus caused by eosinophilic esophagitis in which per-oral endoscopic myotomy resulted in symptom improvement |
| Q49190282 | Ankylosaurus back sign: novel endoscopic finding in esophageal eosinophilia patients indicating proton pump inhibitor response |
| Q64065028 | Association between endoscopic findings of eosinophilic esophagitis and responsiveness to proton pump inhibitors |
| Q39711371 | Beneficial effect of Lactococcus lactis NCC 2287 in a murine model of eosinophilic esophagitis |
| Q89406548 | Changing Concept of the Prevalence of Eosinophilic Esophagitis: Visible and Hidden Patients |
| Q41010688 | Clinical Applications of the Eosinophilic Esophagitis Diagnostic Panel |
| Q90301521 | Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS) |
| Q47422883 | Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum |
| Q49186926 | Current concepts in eosinophilic esophagitis |
| Q49540104 | Determinant factors of quality of life in adult patients with eosinophilic esophagitis. |
| Q45072840 | Diagnosis and Management of Eosinophilic Esophagitis |
| Q39155749 | Diagnosis and treatment of eosinophilic esophagitis in clinical practice |
| Q53076228 | Diagnostic Trends and Clinical Characteristics of Eosinophilic Esophagitis: A Korean, Single-center Database Study. |
| Q60300286 | Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis—Current Concepts and Perspectives for Steroid Use |
| Q33791211 | Effect of topical beclomethasone on inflammatory markers in adults with eosinophilic esophagitis: A pilot study |
| Q42371575 | Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression |
| Q93354745 | Eosinophilic Esophagitis |
| Q55085242 | Eosinophilic Esophagitis Is an Underlying Cause for Gastrointestinal Concerns in Children. |
| Q47559116 | Eosinophilic Esophagitis: Relationship of Subepithelial Eosinophilic Inflammation With Epithelial Histology, Endoscopy, Blood Eosinophils, and Symptoms |
| Q58578278 | Eosinophilic Esophagitis: Review and Update |
| Q49891945 | Eosinophilic Esophagitis: an Important Comorbid Condition of Asthma? |
| Q49590768 | Eosinophilic Gastrointestinal Disorders Pathology |
| Q52776036 | Eosinophilic esophagitis and proton pump inhibitors: is there a new link? |
| Q30244585 | Eosinophilic esophagitis in an octogenarian: A case report and review of the literature |
| Q90168965 | Eosinophilic esophagitis incidence in New Zealand: high but not increasing |
| Q38707910 | Eosinophilic esophagitis is characterized by a non-IgE-mediated food hypersensitivity. |
| Q90136076 | Eosinophilic esophagitis: Current concepts in diagnosis and treatment |
| Q89017249 | Eosinophilic esophagitis: an underdiagnosed cause of dysphagia and food impaction to be recognized by otolaryngologists |
| Q38911033 | Eosinophilic esophagitis: current perspectives from diagnosis to management. |
| Q39251666 | Eosinophilic esophagitis: unclear roles of IgE and eosinophils |
| Q38642524 | Epidemiology and Natural History of Eosinophilic Esophagitis |
| Q42353444 | Esophagitis and its causes: Who is "guilty" when acid is found "not guilty"? |
| Q36229922 | Food allergy and the gut. |
| Q58564335 | Gastro-oesophageal reflux disease and eosinophilic oesophagitis: What is the relationship? |
| Q30234446 | Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. |
| Q88765935 | How I Approach the Management of Eosinophilic Esophagitis in Adults |
| Q47156583 | Improvement in Esophageal Distensibility in Response to Medical and Diet Therapy in Eosinophilic Esophagitis |
| Q38660542 | Incidence of eosinophilic esophagitis in the Netherlands continues to rise: 20-year results from a nationwide pathology database |
| Q36054472 | JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. |
| Q47182041 | Lack of proton pump inhibitor trial prior to commencing therapy for eosinophilic esophagitis is common in the community |
| Q53756480 | Letter: proton pump inhibitor-responsive oesophageal eosinophilia - more than just gastro-oesophageal reflux disease. |
| Q57172852 | Longitudinal Growth Outcomes Following First Line Treatment For Pediatric Eosinophilic Esophagitis Patients |
| Q47676068 | Management of eosinophilic esophagitis in daily clinical practice |
| Q38680027 | Management of refractory eosinophilic oesophagitis |
| Q28069985 | Managing eosinophilic esophagitis: challenges and solutions |
| Q89978137 | Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis |
| Q56350244 | New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting |
| Q47767767 | Pediatric Eosinophilic Esophagitis Endotypes: Are We Closer to Predicting Treatment Response? |
| Q38837172 | Pharmacological treatment of eosinophilic gastrointestinal disorders |
| Q90741728 | Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research |
| Q40053113 | Prenatal, intrapartum, and postnatal factors are associated with pediatric eosinophilic esophagitis |
| Q40093651 | Presentation and Epidemiology of Gastroesophageal Reflux Disease |
| Q37166333 | Prevalence of Eosinophilic Esophagitis and Lymphocytic Esophagitis in Adults with Esophageal Food Bolus Impaction. |
| Q50186814 | Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: A Paradigm Shift |
| Q41501186 | Proton pump inhibitor-responsive oesophageal eosinophilia: too early to change clinical practice |
| Q39100795 | Quality assessment of clinical practice guidelines for eosinophilic esophagitis using the AGREE II instrument. |
| Q88971231 | RNA sequencing confirms similarities between PPI-responsive oesophageal eosinophilia and eosinophilic oesophagitis |
| Q42367243 | Recent advances in eosinophilic esophagitis |
| Q88040792 | Response to Ishimura et al |
| Q50052517 | Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007-2016). |
| Q47751408 | Serum Biomarkers for the Diagnosis of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis |
| Q47817092 | Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients |
| Q38714333 | Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors |
| Q56889245 | The Global Face of Eosinophilic Esophagitis: Advocacy and Research Groups |
| Q54936077 | The Role of Proton Pump Inhibitors in the Management of Pediatric Eosinophilic Esophagitis. |
| Q39215912 | The pathology and causes of tissue eosinophilia in the gastrointestinal tract. |
| Q48248127 | The role of endoscopy in eosinophilic esophagitis: from diagnosis to therapy. |
| Q47822563 | The role of maintenance therapy in eosinophilic esophagitis: who, why, and how? |
| Q38813019 | The role of proton pump inhibitor therapy in the management of eosinophilic esophagitis |
| Q53821621 | Toll-like receptors-mediated pathways activate inflammatory responses in the esophageal mucosa of adult eosinophilic esophagitis. |
| Q41929663 | Topical glucocorticoid vs. diet therapy in eosinophilic esophagitis: the need for better treatment options |
| Q52651158 | Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach. |
| Q54957694 | UK guidelines on oesophageal dilatation in clinical practice. |
| Q90229220 | Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference |
| Q45069324 | Using Serum IgE Antibodies to Predict Esophageal Eosinophilia in Children |
| Q52696635 | White Paper AGA: Drug Development for Eosinophilic Esophagitis. |
Search more.